Alexis Borisy, Nicholas Lydon and George Demetri
then-current members of our board of directors who were also founders of IDRx
$78.7 million
August 1, 2022
License of the company's internally discovered KIT exon 13 inhibitor to IDRx in exchange for IDRx Series A preferred stock, with anti-dilution rights, milestones and royalties; the company later received its IDRx shares for $78.7 million when the transaction closed with GSK plc in February 2025.
With IDRx, Inc.
Open in proxy
